Electromagnetic Navigation Versus CT Guided TTNA in the Diagnosis of Early Peripheral Lung Cancer

Electromagnetic Navigation Guided Versus CT-guided Transthoracic Needle Aspiration (TTNA) in the Diagnosis of Early Peripheral Lung Cancer, a Randomized Open Label Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03802266

Enrollment

322

Registered

2019-01-14

Start date

2019-01-01

Completion date

2019-12-30

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

The purpose of this study is to compare Electromagnetic navigation guided with CT-guided transthoracic needle aspiration (TTNA) in the diagnosis of pulmonary peripheral nodule. Primary endpoints：Diagnostic rate Secondary endpoints：operating time、adverse events Study design: Multicenter、randomized、open lebel

Interventions

DEVICEElectromagnetic Navigation guided transthoracic needle aspiration

Patients in this group will receive electromagnetic navigation guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule

DEVICECT-guided Transthoracic Needle Aspiration

Patients in this group will receive CT guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients with 0.8-3 cm, high-risk pulmonary peripheral nodules that need biopsy for pathological diagnosis; 2. Patients who are older than 18 year-old; 3. Patients voluntarily join the study and give written informed consent for the study.

Exclusion criteria

1. Chest CT scan shows that the pulmonary nodule is pure ground glass opacity. 2. Large blood vessels or important structures on the puncture path of peripheral lung tumors； 3. Severe cardiopulmonary dysfunction and other indications that can't receive bronchoscopy.

Design outcomes

Primary

Measure	Time frame
Diagnostic rate	18 months

Secondary

Measure	Time frame
Operating time	18 months
Adverse events	18 months

Countries

China

Contacts

Primary ContactHua Zhong, Phd，MD

eddiedong8@hotmail.com13818200560

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026